Navigation Links
Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
Date:12/5/2007

BETHESDA, Md., Dec. 5 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammation and autoimmune diseases, today announced that Dr. Christian Itin, President and Chief Executive Officer of Micromet, will be part of a panel discussion titled "Delivering On The Promise Of Antibody Therapies For Cancer" at the 2007 RBC Capital Markets Healthcare Conference in New York, on Wednesday, December 12, 2007 at 3:30pm Eastern Time (9:30pm Central European Time).

An audio webcast of Dr. Itin's remarks will be available live and accessible through Micromet's website at http://www.micromet-inc.com, as well as a replay and download of the presentation slides following the event.

About Micromet, Inc. (http://www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company focusing on the development of novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Three of its antibodies are in clinical development. MT103 (MEDI-538), the first antibody developed using the BiTE(R) technology platform to be clinically validated in Micromet's product pipeline, is being evaluated in a phase 1 clinical trial for the treatment of patients with non- Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, a subsidiary of AstraZeneca plc. The second clinical stage antibody is adecatumumab (MT201), a human monoclonal antibody targeting EpCAM expressing tumors. Adecatumumab is being developed by Micromet in collaboration with Merck Serono, a division of Merck KGaA in Darmstadt, Germany, in a phase 1b clinical trial evaluating MT201 in combination
'/>"/>

SOURCE Micromet, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
8. Avicena Group to Present at Noble Financial Conference
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
11. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... July 14, 2014 Throughout this ... across the clinical trials space, representing 38 countries ... series entitled “Optimizing Patient Participation in Clinical Trials. ... off with internationally renowned R&D expert, Ken Getz, ... on Reinventing Drug Development through Patient Centricity. , ...
(Date:7/14/2014)... Mass. , July 14, 2014 Minerva ... the development of new therapies to treat neuropsychiatric diseases ... has been appointed vice president of finance and ... Mr. Ahlholm is a senior executive with more than ... at technology and life science companies. His background includes ...
(Date:7/14/2014)... Mateo, CA (PRWEB) July 14, 2014 ... CONNECT patient registry platform, announced that three ... muscular dystrophies; the Phelan-McDermid Syndrome International Registry; ... Nephrotic Syndrome—have been awarded contracts by the ... of the creation of a new health ...
(Date:7/13/2014)... R.I. (Brown University) -- The discovery 30 years ago ... an explosion of nanotechnology research. Now, there appears to ... from Brown University, Shanxi University and Tsinghua University in ... atoms forms a hollow molecular cage similar to a ... boron cage structurepreviously only a matter of speculationdoes indeed ...
Breaking Biology Technology:Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 2Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 3Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 4Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 5Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer 2PatientCrossroads Fuels Development of New National Clinical Research Network 2PatientCrossroads Fuels Development of New National Clinical Research Network 3Researchers discover boron 'buckyball' 2Researchers discover boron 'buckyball' 3
... (the,"Company") (OTC Bulletin Board: TBIO) today announced financial results ... results are,presented in the tables that follow. Second ... of $0.2 million or $0.00 per share,for the second ... of $0.4 million or,$0.01 per share for the second ...
... Mass., Aug. 14 Avitar, Inc. (OTC,Bulletin Board: AVTI) ... ended June 30, 2007. For the quarter ended ... operations compared to $1,202,000 from continuing,operations for the quarter ... amounted to $597,000 versus $696,000. The net income,was $301,000, ...
... -- China Medical,Technologies, Inc. (the "Company") (Nasdaq: ... develops, manufactures and markets advanced in-,vitro diagnostic products ... announced that it will participate in the Morgan,Stanley,s ... Kong Date: August 21, 2007 China ...
Cached Biology Technology:Transgenomic, Inc. Reports Second Quarter 2007 Results 2Transgenomic, Inc. Reports Second Quarter 2007 Results 3Transgenomic, Inc. Reports Second Quarter 2007 Results 4Transgenomic, Inc. Reports Second Quarter 2007 Results 5Transgenomic, Inc. Reports Second Quarter 2007 Results 6Transgenomic, Inc. Reports Second Quarter 2007 Results 7Transgenomic, Inc. Reports Second Quarter 2007 Results 8Avitar Reports Third Quarter Financial Results for Fiscal 2007 2Avitar Reports Third Quarter Financial Results for Fiscal 2007 3Avitar Reports Third Quarter Financial Results for Fiscal 2007 4
(Date:7/14/2014)... have shown how the main psychoactive ingredient in cannabis ... Research published today reveals the existence of previously unknown ... in shrinking tumours. , It is hoped that ... anti-cancer properties. , The research was co-led ... used samples of human breast cancer cells to induce ...
(Date:7/13/2014)... of more effective treatments for cachexia, a profound wasting ... all cancer patients, raising their risk of death, according ... have been tried to reverse the condition, which may ... treatments, but none have had great success. , Scientists ... Nature , led by Bruce Spiegelman, PhD, demonstrated ...
(Date:7/11/2014)... awarded Michael F. Holick, PhD, MD, of Boston University ... Avioli Award. Holick, a professor of medicine, physiology and ... understanding of vitamin D and its role in disease ... the American Society for Bone and Mineral Research (ASBMR) ... It is named for ASBMR,s first president and founding ...
Breaking Biology News(10 mins):UEA research reveals how cannabis compound could slow tumour growth 2Antibody halts cancer-related wasting condition 2Antibody halts cancer-related wasting condition 3BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2
... a drink problem, there is a greater risk that you ... from the Sahlgrenska Academy, at the University of Gothenburg, Sweden. ... 50% more likely to have a drink problem in the ... new light on this link. Carried out by researcher Anna ...
... LAWRENCE University of Kansas scientists have found new evidence ... (LCPUFA) are good for developing brains and hearts. In ... of four formulas from birth to 12 months; three with ... formula with no LCPUFA, and tested at four, six and ...
... our understanding of genetics and biological processes in all animals, ... of animals, scientists are still finding the fruit fly to ... the University of Rochester. The latest revelation has to ... fruit flies. It was widely accepted that all X chromosomes ...
Cached Biology News:New thinking on regulation of sex chromosomes in fruit flies 2
... These handy dispensers save space and ... and other garb. They are the ... parts used in labs, processing and ... charges and the particles they attract. ...
... 2 NaO 7 S 2 Formula Weight: ... Identity: By IR epsilon max (615 nm, ... equal to 60 x 10 3 Loss ... lambda max (H 2 O solution): ...
...
... research-grade spectrofluorometer with a minimum 1 nm ... 200 or greater for the Raman band ... to keep in mind in order to ... titration, or anisotropic measurements. ,The FP-6500 is ...
Biology Products: